文献速递湿疹皮炎与荨麻疹

特应性皮炎:发病机制及新型全身治疗选择的研究启示

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-01-01

本综述描述特应性皮炎涉及的多样细胞与分子机制,包括T细胞驱动炎症(主要为Th2和Th17来源细胞因子,多经JAK信号通路介导)与感觉神经元通路相互作用导致瘙痒、疼痛和睡眠障碍;分子通路阐明使治疗从广谱全身免疫抑制转向JAK抑制剂和细胞因子特异性生物制剂等靶向药物,临床开发证据强化并扩展了对发病机制的理解,有望实现针对特定亚型的个体化治疗。

要点

  • 特应性皮炎为慢性异质性炎症性皮肤病,临床表现反映多种病理生理机制及遗传、免疫失调与环境因素的相互作用。
  • T细胞驱动炎症(主要为Th2和Th17来源细胞因子,多经JAK信号通路介导)与感觉神经元通路相互作用,参与瘙痒、疼痛和睡眠障碍。
  • 分子通路阐明促使治疗从广谱全身免疫抑制转向JAK抑制剂和细胞因子特异性生物制剂等靶向药物。

核心结论

  • 靶向治疗临床开发证据强化并扩展了对特应性皮炎发病机制的理解,有望实现针对特定亚型的个体化治疗策略。

研究设计与样本

  • 本文为综述,描述特应性皮炎涉及的多样细胞和分子机制及新型全身治疗选择的启示。

主要发现

  • 特应性皮炎为慢性异质性炎症性皮肤病,通常始于儿童期并常持续至成年,与高皮肤相关健康负担相关。
  • T细胞驱动炎症主要为Th2和Th17来源细胞因子,许多由Janus激酶(JAK)信号通路介导。
  • 局部炎症过程与感觉神经元通路相互作用,参与瘙痒、疼痛和睡眠障碍等临床表现。
  • 治疗策略从广谱全身免疫抑制治疗演变为JAK抑制剂和细胞因子特异性生物制剂等靶向药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis (AD) is a chronic, heterogenous, inflammatory skin disorder associated with a high skin-related health burden, typically starting in childhood and often persisting into adulthood. AD is characterized by a wide range of clinical phenotypes, reflecting multiple underlying pathophysiological mechanisms and interactions between genetics, immune system dysregulation and environmental factors. In this review, we describe the diverse cellular and molecular mechanisms involved in AD, including the critical role of T-cell-driven inflammation, primarily via T helper (Th) 2- and Th17-derived cytokines, many of which are mediated by the Janus kinase (JAK) signaling pathway. These local inflammatory processes interact with sensory neuronal pathways, contributing to the clinical manifestations of AD, including itch, pain and sleep disturbance. The recent elucidation of the molecular pathways involved in AD has allowed treatment strategies to evolve from broad-acting systemic immunosuppressive therapies to more targeted agents, including JAK inhibitors and cytokine-specific biologic agents. Evidence from the clinical development of these targeted therapies has reinforced and expanded our understanding of the pathophysiological mechanisms underlying AD and holds promise for individualized treatment strategies tailored to specific AD subtypes.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bieber T, Paller AS, Kabashima K, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. J Eur Acad Dermatol Venereol. 2022. PMID: 35575442. doi:10.1111/jdv.18225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。